Cargando…
Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario
The COVID-19 pandemic has a significant impact on cancer patients and the delivery of cancer care. To allow clinicians to adapt treatment plans for patients, Ontario Health (Cancer Care Ontario) issued a series of interim funding measures for the province’s New Drug Funding Program (NDFP), which cov...
Autores principales: | Naipaul, Rohini D., Mercer, Rebecca E., Chan, Kelvin K. W., Yeung, Lyndee, Forbes, Leta, Gavura, Scott |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025744/ https://www.ncbi.nlm.nih.gov/pubmed/33652898 http://dx.doi.org/10.3390/curroncol28020103 |
Ejemplares similares
-
Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada
por: Habbous, Steven, et al.
Publicado: (2022) -
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer
por: Raphael, Michael J., et al.
Publicado: (2021) -
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
por: Chan, Kelvin, et al.
Publicado: (2020) -
Are population‐based patient‐reported outcomes associated with overall survival in patients with advanced pancreatic cancer?
por: Dai, Wei Fang, et al.
Publicado: (2019) -
Broad funding for oxaliplatin in Ontario (finally!)
por: Jonker, D., et al.
Publicado: (2007)